Seer
PrognomiQ Closes $34M Series D Round
The company said it will use the funding for development of its blood-based early detection test for lung cancer, which it plans to offer initially as an LDT and then as an IVD.
The company shared results from a larger case-control study in a recent preprint, and has already begun recruiting for a large prospective follow-up.
The Seer spinoff recently closed a $46 million funding round that it is using to support efforts in nucleic acid, proteomic, and metabolomic biomarker discovery.
PrognomiQ Closes $46M Financing Round
The firm, a spinoff of proteomics company Seer, said it will use the funds to accelerate its multiomic tests for cancer early detection, treatment selection, and patient monitoring.